Tender

Advert for Collaborator in Biological Research for Topical Product to assist with Scalp Cooling during Chemotherapy

PAXMAN COOLERS LIMITED

This public procurement record has 1 release in its history.

Tender

13 Jul 2022 at 13:25

Tender Notice
Summary of the contracting process

Paxman Coolers Limited is seeking a collaborator in biological research for a topical product designed to assist with scalp cooling during chemotherapy. The tender, titled "Advert for Collaborator in Biological Research for Topical Product to assist with Scalp Cooling during Chemotherapy", falls under the medical equipment and pharmaceuticals category. The current procurement stage is open for tender submissions, with a deadline for submissions set for 25th July 2022. The contract is anticipated to commence on 8th August 2022 and will last until 28th February 2023. The estimated value of the contract is £100,000, with a minimum value of £87,500 set to foster competitive bids.

This tender presents substantial opportunities for businesses specializing in cell biology, skin research, and pharmaceutics, particularly those with expertise in formulating topical agents for targeted delivery of antioxidants to hair follicles. Small and medium-sized enterprises (SMEs) and voluntary, community, and social enterprises (VCSEs) are encouraged to participate in this procurement, leveraging their innovative capabilities to enhance the efficacy of scalp cooling treatments for chemotherapy patients. Engaging in this contract could lead to valuable partnerships in the healthcare sector, where the need for effective solutions to mitigate chemotherapy-induced hair loss is increasingly recognized.

Find more tenders on our Open Data Platform.
How relevant is this notice?

D3 Tenders Premium

Win More Public Sector Contracts

AI-powered tender discovery, pipeline management, and market intelligence — everything you need to grow your public sector business.

Start Free Trial Book a Demo
All Features Pricing

Notice Information

Notice Title

Advert for Collaborator in Biological Research for Topical Product to assist with Scalp Cooling during Chemotherapy

Notice Description

Paxman is a medical technology company with an established leadership position in the Scalp Cooling sector. The Paxman Scalp Cooling System (PSCS) minimizes hair loss in connection with chemotherapy treatment. The product is distributed to over 60 markets internationally, including: France, Germany, The Netherlands, Switzerland, Sweden, Russia, Brazil, Mexico, Australia, and the U.S. Scalp cooling is an important treatment, which has a strong clinical support and is a fully established therapy in many countries throughout the world. Chemotherapy-induced alopecia is the most feared side effect of treatment in >75% of patients. Often patients feel this is the most traumatic side effect of their cancer treatment and not only can it lead to social isolation, but hair loss can affect self-image more than breast surgery. Eight percent of patients refuse chemotherapy or request a less efficacious treatment due to the prospect of hair loss. The company has extensive global experience - since 2003, more than 65 clinical studies have been conducted in more than 17 countries and includes the first-ever randomized clinical trial to evaluate modern scalp cooling, which took place at several Cancer Centers in the United States as part of the FDA (Food and Drug Administration) clearance process. As part of Paxman's investment in biological research, it has been discovered that chemotherapy drugs induce oxidative stress inside cells of the hair follicles which causes cell toxicity (and ultimately hair loss). Therefore, a novel patented combinatorial approach was designed to reduce cell toxicity at "sub-optimal" cooling temperatures and has the potential to dramatically enhance the efficacy of the Paxman scalp cooling device. This intervention combines cooling with treatment with a reactive oxygen species (ROS) inhibitor (antioxidant compound) delivered into cells to reduce oxidative stress (and these findings have been confirmed using whole follicles mini-organ cultures). Using in vitro models, the company have now established a panel of antioxidant compounds which has shown extremely good efficacy in minimising or preventing cytotoxicity in combination with cooling. Paxman now need the expertise to be able to target these antioxidant compounds to human hair follicles of the scalp. This will require expertise in pharmaceutics in order to prepare topical agents with appropriate formulations for delivery of these antioxidants to the hair follicles. The identified third-party organisation must have both the cell biology/skin research as well as pharmaceutics expertise and research capabilities in order to be in position to deliver the proposed project.

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-b5fd17-58505d9c-3c1d-450e-9e47-ab8f17a6f425
Publication Source
Contracts Finder
Latest Notice
https://www.contractsfinder.service.gov.uk/Notice/9ef6fd49-0e3d-48b4-ad90-f75d0bf4e20f
Current Stage
Tender
All Stages
Tender

Procurement Classification

Notice Type
Tender Notice
Procurement Type
Standard
Procurement Category
Services
Procurement Method
Open
Procurement Method Details
Open procedure (below threshold)
Tender Suitability
SME, VCSE
Awardee Scale
Not specified

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products

CPV Codes

33000000 - Medical equipments, pharmaceuticals and personal care products

Notice Value(s)

Tender Value
£100,000 £100K-£500K
Lots Value
Not specified
Awards Value
Not specified
Contracts Value
Not specified

Notice Dates

Publication Date
13 Jul 20223 years ago
Submission Deadline
25 Jul 2022Expired
Future Notice Date
Not specified
Award Date
Not specified
Contract Period
7 Aug 2022 - 28 Feb 2023 6-12 months
Recurrence
Not specified

Notice Status

Tender Status
Active
Lots Status
Not Specified
Awards Status
Not Specified
Contracts Status
Not Specified

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
PAXMAN COOLERS LIMITED
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
HUDDERSFIELD
Postcode
HD8 0LE
Post Town
Huddersfield
Country
England
Major Region (ITL 1)
TLE Yorkshire and The Humber
Basic Region (ITL 2)
TLE4 West Yorkshire
Small Region (ITL 3)
TLE44 Calderdale and Kirklees
Delivery Location
Not specified
Local Authority
Kirklees
Electoral Ward
Almondbury
Westminster Constituency
Huddersfield

Further Information

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

Download

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts. 

{
    "tag": [
        "compiled"
    ],
    "id": "ocds-b5fd17-58505d9c-3c1d-450e-9e47-ab8f17a6f425-2022-07-13T14:25:57+01:00",
    "date": "2022-07-13T14:25:57+01:00",
    "ocid": "ocds-b5fd17-58505d9c-3c1d-450e-9e47-ab8f17a6f425",
    "language": "en",
    "initiationType": "tender",
    "tender": {
        "id": "Paxman 1119795",
        "title": "Advert for Collaborator in Biological Research for Topical Product to assist with Scalp Cooling during Chemotherapy",
        "description": "Paxman is a medical technology company with an established leadership position in the Scalp Cooling sector. The Paxman Scalp Cooling System (PSCS) minimizes hair loss in connection with chemotherapy treatment. The product is distributed to over 60 markets internationally, including: France, Germany, The Netherlands, Switzerland, Sweden, Russia, Brazil, Mexico, Australia, and the U.S. Scalp cooling is an important treatment, which has a strong clinical support and is a fully established therapy in many countries throughout the world. Chemotherapy-induced alopecia is the most feared side effect of treatment in >75% of patients. Often patients feel this is the most traumatic side effect of their cancer treatment and not only can it lead to social isolation, but hair loss can affect self-image more than breast surgery. Eight percent of patients refuse chemotherapy or request a less efficacious treatment due to the prospect of hair loss. The company has extensive global experience - since 2003, more than 65 clinical studies have been conducted in more than 17 countries and includes the first-ever randomized clinical trial to evaluate modern scalp cooling, which took place at several Cancer Centers in the United States as part of the FDA (Food and Drug Administration) clearance process. As part of Paxman's investment in biological research, it has been discovered that chemotherapy drugs induce oxidative stress inside cells of the hair follicles which causes cell toxicity (and ultimately hair loss). Therefore, a novel patented combinatorial approach was designed to reduce cell toxicity at \"sub-optimal\" cooling temperatures and has the potential to dramatically enhance the efficacy of the Paxman scalp cooling device. This intervention combines cooling with treatment with a reactive oxygen species (ROS) inhibitor (antioxidant compound) delivered into cells to reduce oxidative stress (and these findings have been confirmed using whole follicles mini-organ cultures). Using in vitro models, the company have now established a panel of antioxidant compounds which has shown extremely good efficacy in minimising or preventing cytotoxicity in combination with cooling. Paxman now need the expertise to be able to target these antioxidant compounds to human hair follicles of the scalp. This will require expertise in pharmaceutics in order to prepare topical agents with appropriate formulations for delivery of these antioxidants to the hair follicles. The identified third-party organisation must have both the cell biology/skin research as well as pharmaceutics expertise and research capabilities in order to be in position to deliver the proposed project.",
        "datePublished": "2022-07-13T14:25:57+01:00",
        "status": "active",
        "classification": {
            "scheme": "CPV",
            "id": "33000000",
            "description": "Medical equipments, pharmaceuticals and personal care products"
        },
        "items": [
            {
                "id": "1",
                "deliveryAddresses": [
                    {
                        "postalCode": "HD8 0LE"
                    }
                ]
            }
        ],
        "minValue": {
            "amount": 87500,
            "currency": "GBP"
        },
        "value": {
            "amount": 100000,
            "currency": "GBP"
        },
        "procurementMethod": "open",
        "procurementMethodDetails": "Open procedure (below threshold)",
        "tenderPeriod": {
            "endDate": "2022-07-25T17:00:00+01:00"
        },
        "contractPeriod": {
            "startDate": "2022-08-08T00:00:00+01:00",
            "endDate": "2023-02-28T23:59:59Z"
        },
        "suitability": {
            "sme": true,
            "vcse": true
        },
        "mainProcurementCategory": "services",
        "documents": [
            {
                "id": "1",
                "documentType": "tenderNotice",
                "description": "Opportunity notice on Contracts Finder",
                "url": "https://www.contractsfinder.service.gov.uk/Notice/9ef6fd49-0e3d-48b4-ad90-f75d0bf4e20f",
                "datePublished": "2022-07-13T14:25:57+01:00",
                "format": "text/html",
                "language": "en"
            },
            {
                "id": "2",
                "documentType": "technicalSpecifications",
                "description": "Project Plan",
                "url": "https://www.contractsfinder.service.gov.uk/Notice/Attachment/120ccac2-f346-4272-8cb5-66bef7603745",
                "format": "application/vnd.openxmlformats-officedocument.wordprocessingml.document"
            },
            {
                "id": "3",
                "documentType": "biddingDocuments",
                "description": "Response form",
                "url": "https://www.contractsfinder.service.gov.uk/Notice/Attachment/7aae2d94-6ad3-4fac-815b-e4535e931553",
                "format": "application/vnd.openxmlformats-officedocument.wordprocessingml.document"
            }
        ]
    },
    "parties": [
        {
            "id": "GB-SRS-sid4gov.cabinetoffice.gov.uk/HFKu89Yj",
            "name": "PAXMAN COOLERS LIMITED",
            "identifier": {
                "legalName": "PAXMAN COOLERS LIMITED",
                "scheme": "GB-SRS",
                "id": "sid4gov.cabinetoffice.gov.uk/HFKu89Yj"
            },
            "address": {
                "streetAddress": "International House,Penistone Road, Fenay Bridge",
                "locality": "HUDDERSFIELD",
                "postalCode": "HD80LE",
                "countryName": "England"
            },
            "contactPoint": {
                "name": "Liza Hirst",
                "email": "liza@paxmanscalpcooling.com",
                "telephone": "01484349444"
            },
            "details": {
                "url": "http://www.paxmanscalpcooling.com"
            },
            "roles": [
                "buyer"
            ]
        }
    ],
    "buyer": {
        "id": "GB-SRS-sid4gov.cabinetoffice.gov.uk/HFKu89Yj",
        "name": "PAXMAN COOLERS LIMITED"
    }
}